Related Experiment Video

Updated: Jun 7, 2026

Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction
06:01

Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction

Published on: October 6, 2022

[Signal transduction in urothelial cancer: how exactly do we know the targets for targeted therapy?]

G Niegisch1, A Koch, J Knievel

  • 1Urologische Klinik, Medizinische Fakultät, Heinrich-Heine-Universität, Moorenstraße 5, 40625 Düsseldorf, Deutschland. Guenter.Niegisch@med.uni-duesseldorf.de

Der Urologe. Ausg. A
|October 21, 2010
PubMed

Insights

Targeted therapies show limited success in urothelial carcinoma due to incomplete understanding of its molecular pathways. Further research into epigenetic regulation of cancer pathways is crucial for developing effective treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genomics

Context:

  • Urothelial carcinoma (UC) treatment has seen progress with targeted therapies, driven by understanding cancer signaling pathways.
  • Specific genetic alterations like FGFR3, HRAS, and PIK3CA mutations are identified in UC, impacting MAPK and Akt pathways, particularly in papillary subtypes.
  • Invasive UC often involves dysregulation of cell cycle control genes such as RB1 and p53.

Purpose:

  • To investigate the molecular underpinnings of urothelial carcinoma (UC) signaling pathways.
  • To identify the reasons for the limited efficacy of current targeted therapies in UC treatment.
  • To explore the role of epigenetic mechanisms in regulating cancer pathway target genes in UC.

Summary:

  • While targeted therapies have advanced cancer care, their efficacy in urothelial carcinoma (UC) remains limited.
  • Genetic mutations in UC affect key signaling pathways (MAPK, Akt) and cell cycle regulators (RB1, p53).
  • Epigenetic regulation of cancer pathway genes is a critical, yet underexplored, factor in UC pathogenesis and therapeutic response.

Impact:

  • Highlights the need for a deeper understanding of UC molecular biology beyond genetic mutations.
  • Suggests that targeting epigenetic mechanisms could offer novel therapeutic strategies for urothelial carcinoma.
  • Emphasizes the importance of elucidating gene regulation for future precision medicine approaches in UC.

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...